Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

Patients with atopic dermatitis had an increased risk for COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.